GSK plc business relationships
Companies named in GSK plc’s 20-F filed 2026-03-06, and public companies whose annual reports name GSK plc. Each link shows the sentence it came from. Scores are Engagemii’s AI visibility scores.
- AEO visibility
- 5.5 / 10
- AI naming
- 83 / 100 Top 1% in its category
- Agent readiness
- 35 / 100
- AI adoption
- 0 / 100
Named in GSK plc’s annual report 0
No company named in this filing matched a company in the map.
Companies whose annual reports name GSK plc 70
“Ofatumumab was originally developed by Genmab and licensed to GlaxoSmithKline (GSK).” SEC filing
“...ng TCV includes the total potential value of the company's strategic collaborations with AstraZeneca AB, or AstraZeneca, and GlaxoSmithKline, or GSK, which, although listed under the Data and applications product line, could be satisfied by the purchase of any of the company's products and services.” SEC filing
“...Phase 3 clinical trial costs performed by Pfizer, and €6.5 million (all non-current) related to the expected payment to GSK related to the termination of the strategic alliance agreement in 2019, and €1.1 million (all current) related to refund liabilities to customers related to rebate and refund p...” SEC filing
“...td., Aro Biotherapeutics, Arrowhead and its collaborators, AstraZeneca, Dyne Therapeutics, Inc., Eli Lilly and Company, GlaxoSmithKline plc, Novartis, Novo Nordisk A/S, SanegeneBio, Sarepta Therapeutics, Inc., Silence Therapeutics plc, Takeda Pharmaceutical Company Ltd., and Wave Life Sciences, Ltd....” SEC filing
“The Company had three collaboration customers during the year-ended December 31, 2024, which are Galapagos, Genentech and GSK, and two customers to whom product revenue sales were made.” SEC filing
“...operations primarily through sales of equity securities, cash receipts under our Astellas Collaboration Agreement, Galapagos, Genentech and GSK Collaboration and License Agreements and GSK Termination and Transfer Agreement, government grants and research and development tax and expenditure credits.” SEC filing
“Genentech and GSK collaborations” SEC filing
“As a result of this liability accounting, even though the royalties are remitted directly to HCR, we record these royalties from GSK as revenue.” SEC filing
“Among other provisions, the license rights granted to GSK survive expiration of the GSK License Agreement.” SEC filing
“We do not incur clinical development costs for products partnered with GSK.” SEC filing
“The mRNA portfolio resulting from the GSK-CureVac collaboration focuses on vaccines in the prevention of influenza and COVID-19 viruses.” SEC filing
“Genmab and GlaxoSmithKline (GSK) entered a co-development and collaboration agreement for ofatumumab” SEC filing
“Amendment #5 to the Research, Development and License Agreement by and between the Registrant, Glaxo Group Limited and GlaxoSmithKline Intellectual Property Development Limited dated June 27, 2014 , filed as an exhibit to the Registrant's Quarterly Report on Form 10-Q for the quarter ended June 30,...” SEC filing
“Therefore, we do not have any remaining performance obligations under our collaboration with GSK.” SEC filing
“Our license agreement with Penn provides that should the rights Penn licensed to GSK ever revert to Penn, such rights shall automatically be included in our license agreement with Penn.” SEC filing
“The last to expire patent under the GSK license agreement, absent patent term” SEC filing
“Going forward, we expect a nominal amount of license and collaboration revenue, if any, from our 2020 GSK Agreement, and we may incur negative license and collaboration revenue related to costs for ongoing required support efforts that our partner GSK leads.” SEC filing
“from China's 3SBio, and a collaboration between GSK and Hengrui Pharmaceuticals valued up to $12 billion, demonstrating that” SEC filing
“GSK Out-licensing Agreement” SEC filing
“License Agreement, dated as of December 16, 2020, by and between Surface Oncology, Inc. and GLAXOSMITHKLINE INTELLECTUAL PROPERTY (No. 4) LIMITED.” SEC filing
“Collaboration, Option and License Agreement with GSK for Pol Theta and Werner Helicase” SEC filing
“We and GSK collaborated on preclinical research for the Pol Theta and WRN programs.” SEC filing
“Exercising its right to terminate for convenience, GSK terminated the license and research collaboration agreement effective from May 30 2024.” SEC filing
“The amortization is recorded as a reduction to the royalties from GSK.” SEC filing
“Under our agreements with our collaborative partner GSK, GSK has full responsibility for commercialization of RELVAR ® /BREO ® ELLIPTA ® and ANORO ® ELLIPTA ® .” SEC filing
“We are dependent on GSK for the successful commercialization and development of products under the GSK Agreements.” SEC filing
“was responsible for discovery projects in the ubiquitin system, conducted in collaboration with GlaxoSmithKline plc and Teva.” SEC filing
“Wave has initiated a Phase 1/2 study of RNA base-editing oligonucleotide (WVE-0006) to restore wild-type protein in lung and liver disease, a program that has been partnered with GSK.” SEC filing
“...accordance with ASC 606, Revenue from Contracts with Customers ("ASC 606") and concluded that the contract counterparty, GSK, is a customer for the AATD Collaboration prior to GSK exercising its option and, for the Discovery Research Collaboration programs during the target validation research term.” SEC filing
“Collaboration and License Agreement by and between Wave Life Sciences USA, Inc., Wave Life Sciences UK Limited and GlaxoSmithKline Intellectual Property (No. 3), dated as of December 13, 2022” SEC filing
“GSK collaboration programs will transfer to GSK for IND-enabling studies, clinical development and commercialization.” SEC filing
“We are not otherwise obligated to purchase ZEJULA or other licensed products from GSK.” SEC filing
“License and Collaboration Agreement with GSK (Niraparib)” SEC filing
“We will purchase ZEJULA from GSK for commercial use in Hong Kong.” SEC filing
“2016 Platform Technology Transfer and License Agreement with GSK” SEC filing
“At the conclusion of the research collaboration, both GSK and the Company will have the right to develop and commercialize monoclonal and bispecific antibody candidates that incorporate the Company's optimized immune-modulating Fc domains.” SEC filing
“The Company assessed this arrangement in accordance with ASC 606 and concluded that GSK is a customer and there is one combined performance obligation, which includes performance of R&D activities in accordance with a contractual work plan, participation in a joint steering committee, the grant of a...” SEC filing
“For example, our ability to receive certain development and commercial milestone payments and royalties from GSK will depend in significant part on GSK's success and diligence in advancing any licensed compounds and licensed products through development, regulatory approval and commercialization.” SEC filing
“Research, Collaboration and License Agreement with GSK” SEC filing
“There was no collaboration revenue under the GSK Agreement recognized during the year ended December 31, 2025.” SEC filing
“These companies include many of our large innovator and generic pharmaceutical customers, such as Merck, GSK, Novartis, Pfizer Inc., Bristol-Myers Squibb, Kyorin Pharmaceutical Corporation, and Teva Pharmaceuticals, which have significant internal research and development efforts directed at develop...” SEC filing
“To date, we have entered into platform technology licensing agreements with each of GlaxoSmithKline Intellectual Property Development Limited, a subsidiary of GlaxoSmithKline plc ("GSK"), Merck & Co., Inc. ("Merck & Co") and Novartis Pharma AG ("Novartis").” SEC filing
“Under the terms of the GSK License Agreement, GSK will be required to seek an expanded license before it may use PRINT for clinical or commercial purposes.” SEC filing
“For example, we are currently subject to certain restrictions with regard to our ability to enter into collaboration arrangements to use PRINT for the development of inhaled therapeutics using certain identified compounds pursuant to our collaboration with GSK; |” SEC filing
“GSK will also pay royalties based on cumulative annual sales to us in the mid-single digit to mid-teen range.” SEC filing
“Ibrexafungerp was licensed to GSK in May 2023.” SEC filing
“Under the GSK License Agreement, GSK is to pay us milestone payments upon our achievement of specified regulatory, commercial and sales milestone events, as well as royalties on sales of ibrexafungerp in those countries in its territory.” SEC filing
“...ities and are party to a number of licensing and collaboration agreements with partners in human health, including: (1) GSK, a pharmaceutical company, which we exclusively (even as to us and our affiliates) provide a, royalty-bearing, sublicensable license for the development, manufacture, and comme...” SEC filing
“...ve License Agreement and Transitional Manufacturing and Supply Agreement, dated as of December 26, 2023, by and between GlaxoSmithKline Intellectual Property (No. 3) Limited, and SCYNEXIS, Inc. (Filed with the SEC as Exhibit 10.41 to our Form 10-K with the SEC on March 28, 2024, SEC File No. 001-363...” SEC filing
“In July 2021, we entered into a Collaboration and License Agreement with GSK, pursuant to which we and GSK collaborate on the global development and commercialization of progranulin-elevating monoclonal antibodies, including nivisnebart, which is currently in a Phase 2 trial, and latozinemab, for wh...” SEC filing
“We are developing, and if successful, plan to commercialize, nivisnebart with our partner GSK.” SEC filing
“Agreement) surrounding GSK-3 inhibitors for Neurodegenerative Disorders were licensed through an Exclusive License Agreement with Equity” SEC filing
“Under GSK Amendment No.3, we were granted royalties upon sales of Jemperli , equal to 8% of Net Sales (as defined in the GSK Agreement) below $1.0 billion, 12% of Net Sales between $1.0 billion and $1.5 billion, 20% of Net Sales between $1.5 billion and $2.5 billion and 25% of Net Sales above $2.5 b...” SEC filing
“Collaboration and Exclusive License Agreement with GSK” SEC filing
“If we are unable to maintain the GSK collaboration, or if this collaboration is not successful, our business could be adversely affected.” SEC filing
“We are heavily dependent on GSK for the successful commercialization and development of Jemperli under the GSK Agreement.” SEC filing
“The current approved drugs for influenza include the neuraminidase inhibitors Tamiflu, Relenza, and Peramivir, anti-influenza drugs that are sold by Roche, Glaxo SmithKline (GSK), and BioCryst partners, respectively.” SEC filing
“Pursuant to the terms of the GSK License Agreement, we granted GSK an exclusive royalty-bearing license, with the right to grant sublicenses, under our intellectual property and regulatory documents and a sublicense under certain intellectual property of Meiji and Meiji's regulatory documents to dev...” SEC filing
“Amendments to the GSK License Agreement” SEC filing
“As a result, we are currently substantially dependent on our tebipenem program and our collaboration with GSK.” SEC filing
“Further, we rely upon Anacor's compliance with its license agreement with GSK to maintain our sublicense to such patents owned by GSK, and any termination of Anacor's license agreement with GSK could result in us losing our license to epetraborole.” SEC filing
“...lude melioidosis, a severe bacterial infection associated with high death rates in endemic regions (funded by the U.S. government), and tuberculosis, a leading cause of death from infectious disease worldwide that affects millions of people each year in partnership with the Gates Foundation and GSK.” SEC filing
“December 23, 2025 we announced that we are going to expand the enrollment of the trial from 21 to 42 patients in collaboration with GSK,” SEC filing
“For example, we have collaborated with Pfizer, GSK and Dana Farber on the development of azenosertib.” SEC filing
“In April 2021, we entered into a clinical trial collaboration and supply agreement with GSK under which we have evaluated the combination of azenosertib and niraparib, GSK's poly (ADP-ribose) polymerase (PARP) inhibitor, in patients” SEC filing
“licensed to GSK and Visirna);” SEC filing
“The change was primarily driven by increased revenue recognition associated with the Sarepta, Sanofi, and GSK license agreements as discussed below.” SEC filing
“Under our licensing and collaboration agreements with Amgen, Takeda, GSK, Sarepta, Visirna, Sanofi, and Novartis, our partners substantially control clinical development and commercialization for all of the candidates covered under those agreements in their relevant territories.” SEC filing
“Health/beauty customers include GlaxoSmithKline, Bayer, Johnson & Johnson, Abbott, Novartis, L'Oréal S.A., Procter & Gamble and Colgate-Palmolive.” SEC filing
“Some of these therapies are manufactured and marketed by large pharmaceutical companies such as Johnson & Johnson, Gilead Sciences, Inc., Bayer Schering Pharma AG, GSK plc, and Merck, as well as a variety of large generic drug manufacturers.” SEC filing
Links are read automatically from SEC annual reports (10-K, 20-F, 40-F). In a hand check of random links, about 8 in 10 were real business relationships, so every link carries its source sentence.